These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2568651)

  • 21. Psychotic symptoms preceding ocular deviation in a patient with tardive oculogyric crises.
    Sachdev P; Tang WM
    Aust N Z J Psychiatry; 1992 Dec; 26(4):666-70. PubMed ID: 1362053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of neuroleptic drugs in plasma and body tissue.
    Pajari KL
    J Clin Psychopharmacol; 1988 Dec; 8(6):446. PubMed ID: 3235705
    [No Abstract]   [Full Text] [Related]  

  • 23. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
    Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
    Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.
    Zhang-Wong J; Beiser M; Zipursky RB; Bean G
    Psychiatry Res; 1998 Dec; 81(3):333-9. PubMed ID: 9925184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma level monitoring of antipsychotic drugs. Clinical utility.
    Dahl SG
    Clin Pharmacokinet; 1986; 11(1):36-61. PubMed ID: 2868820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Side effects during long-term treatment with depot antipsychotic medication.
    Cookson JC
    Clin Neuropharmacol; 1991; 14 Suppl 2():S24-30; discussion S30-2. PubMed ID: 1751940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
    Kirch DG; Jaskiw G; Linnoila M; Weinberger DR; Wyatt RJ
    Psychiatry Res; 1988 Sep; 25(3):233-42. PubMed ID: 2903509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic plasma levels and tardive dyskinesia: a possible link?
    Nasrallah HA
    Schizophr Bull; 1980; 6(1):4-7. PubMed ID: 6102792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic effects on serine and glycine metabolism.
    Baruah S; Waziri R; Sherman A
    Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An importance of dose in antipsychotic combination therapy for schizophrenia.
    Suzuki T
    J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
    [No Abstract]   [Full Text] [Related]  

  • 36. Dysphagia: a rare form of dyskinesia?
    Nieves JE; Stack KM; Harrison ME; Gorman JM
    J Psychiatr Pract; 2007 May; 13(3):199-201. PubMed ID: 17522565
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroleptic plasma levels.
    Van Putten T; Marder SR; Wirshing WC; Aravagiri M; Chabert N
    Schizophr Bull; 1991; 17(2):197-216. PubMed ID: 1679251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.
    Viala A; Ba B; Durand A; Gouezo F; Hou N; Jørgensen A
    Psychopharmacology (Berl); 1988; 94(3):293-7. PubMed ID: 2895936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.